Trials / Completed
CompletedNCT00511706
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 243 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexamethasone | Intravitreal injection of dexamethasone 700 µg at Day 1. |
| BIOLOGICAL | ranibizumab | Ranibizumab 500 µg at day -30 and Day 7-14. |
| OTHER | sham | Sham needle-less injection administered in the study eye at Day 1. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2007-08-06
- Last updated
- 2019-04-25
- Results posted
- 2012-09-03
Locations
9 sites across 9 countries: United States, Australia, France, Israel, Italy, New Zealand, Portugal, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT00511706. Inclusion in this directory is not an endorsement.